%0 Journal Article
%T Biologic Therapy in Head and Neck Cancer: A Road with Hurdles
%A Pol Specenier
%A Jan B. Vermorken
%J ISRN Oncology
%D 2012
%R 10.5402/2012/163752
%X The epidermal growth factor receptor (EGFR) is overexpressed in the vast majority of cases of squamous cell carcinoma of the head and neck (SCCHN). A high EGFR expression is associated with an unfavorable prognosis. Cetuximab is a chimeric human/murine IgG1 antibody which binds with high affinity to the EGFR. It is the only targeted agent which got approval for the treatment of SCCHN from the regulatory agencies of Europe and the United States, both in locoregionally advanced disease, in association with radiation, and in recurrent/metastatic disease. The outcome of trials involving other EGFR-directed monoclonal antibodies, that is, zalutumumab and panitumumab, was consistent with the results with cetuximab. However these trials failed to meet their primary endpoint. The results with EGFR-directed tyrosine kinase inhibitors have been disappointing. Other potential targets for treatment in SCCHN include the entire ErbB family, the vascular endothelial growth factor (VEGF) and its receptor (VEGFR), the insulin-like growth factor 1 receptor (IGF-1R), the insulin receptor (IR), histone deacetylases (HDAC), the mammalian target of rapamycin (mTOR), the platelet-derived growth factor receptor (PDGFR), heat-shock protein 90 (HSP90), nuclear factor-kappa B (NF-¦ĘB), aurora A or B, and phosphatidylinositol 3-kinase (PIK3CA). 1. Introduction Worldwide, squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer and is diagnosed in more than 600,000 patients each year [1]. A better understanding of its biology has been accompanied by the introduction of a large and rapidly expanding number of targeted agents into its management strategies [2]. Planned and ongoing trials in SCCHN involving targeted agents are summarized in Tables 1, 2, 3, and 4 [3]. Potential targets include the epidermal growth factor receptor (EGFR) and the ErbB family, the vascular endothelial growth factor (VEGF) and its receptor (VEGFR), Insulin-like Growth Factor 1 Receptor (IGF-1R), insulin receptor (IR), histone deacetylase (HDAC), mammalian target of rapamycin (mTOR), platelet-derived growth factor (PDGFR), Heat-shock protein 90 (HSP90), Nuclear factor-kappa B (NF-¦ĘB), aurora A or B, phosphatidylinositol 3-kinase (PIK3CA). Table 1: Planned or ongoing trials with cetuximab in SCCHN. Table 2: Targeted agents under investigation in combination with cetuximab. Table 3: Targeted agents under investigation in SCCHN. Table 4: EGFR-directed targeted agents under investigation in SCCHN (other than cetuximab). 2. EGFR-Directed Therapies The Epidermal Growth Factor Receptor
%U http://www.hindawi.com/journals/isrn.oncology/2012/163752/